Post Vaccine Myocarditis and Pneumonitis aka COVID Vaccine Related Pathology


An increased risk of heart inflammation (myocarditis, pericarditis, pneumonitis) has been observed in people who have received COVID 19 vaccines, particularly in males under 30 years of age after the second vaccine dose. It is the mRNA vaccine that induces this effect. For 1-3 days after vaccination some people feel unwell with headaches, chills or a mild fever. This is common and more seen after the second vaccination dose. If unwell most authorities will advise you to rest, drink plenty of fluids and to avoid vigorous exercise until you are feeling better. If symptoms persist a visit to your family medical practitioner is advised. 

A key symptom of myocarditis is chest pain. Other symptoms may include chest heaviness, discomfort or tightening, shortness of breath, faint or dizziness, palpitations or skipped beats. A key feature of pneumonitis is chest pain caused by frictional rubbing of the pleura on the chest wall. Obviously there is no role of stem cells in the treatment of the acute episode. The patient needs to see their GP and a cardiologist or pneumonologist for investigation and treatment. Authorities confirm that the risk of myocarditis and pneumonitis are less than the risk of developing a COVID like illness.

The feature of a long covid symptom such as pneumonitis may include specific or generalised pain to the chest wall. This could also be described as Tietze’s syndrome with inflammation of the costal cartilages as they attach to the sternum. 

stem cells used for post vaccine pneumonitis and covid vaccine related pathology

Stem cells, especially mesenchymal stem cells, have powerful immune regulation and tissue damage repair functions. In recent years mesenchymal stem cells have been widely used in the treatment of viral infections and acute lung injury. Current studies have shown that stem cells can effectively reduce the severe inflammatory response in patients caused by the SARS 2 virus, reduce lung injury, improve lung function, protect and repair the lung and play a key role in alleviating pulmonary fibrosis in COVID 19 patients.

It is important that the respiratory physician is intimately involved with your decision to undergo stem cell therapy. We would suggest that after 6-12 months post covid vaccine or the disease itself is the time that you should discuss with your specialist whether to undergo stem cell infusion. Many may be against the idea or have different reasons to either agree to have it done or reject stem cells. It is up to the patient to obtain consent in writing with their physician before proceeding with stem cells. 

By routine convention and supported by the literature we would use mesenchymal adipose stem cells harvested via mini liposuction from your abdominal wall and introduced to the site via IV infusion as a potentiator of the healing mechanism.


The diagnosis and treatment of pneumonitis post covid vaccine or COVID itself can be challenging. The use of stem cells for myocarditis even more so. Prior to consideration of stem cells for either of these conditions we would require approval from your respective specialists to undergo the treatment of mini liposuction and IV stem cell infusion. We would recommend that prior to treatment you have all the routine tests done by your cardiologist or pneumonlogist and provide a letter of approval from them. We would be happy to liaise with your specialist physician.

At we pride ourselves on ensuring patients know the team diagnosing and conducting their stem cell therapy. Professor Russell Vickers is the lead specialist, working within a team of specialist surgeons and doctors.

Important questions that patients should ask of any treating clinicians and facility:

  • Are my treating doctors specialist surgeons/doctors and stem cell experts?
  • How many publications and research based studies have they published in peer reviewed journals?
  • Can they augment stem cell therapy with the known benefits of adjunctive therapy? is Europes premier stem cell organisation guided by evidence based medicine and clinical research.

Our founding director, Professor Russell Vickers PhD, MDsc, M Med, MA, FFPM (ANZCA) is an Australian and New Zealand board registered surgeon with over 100 publications, books and thousands of invited lectures and presentations on stem cells, pain, peptide synthesis and biochemistry. Professor Vickers is the leader of a family team of surgeons assisting him including Dr Peter Vickers, MD, FRCS (Edinburgh), FRACDS, Dr Richard Vickers, MD, FRCS (England, Glasgow, Ireland), FRACDS (OMS) and Dr Jessica Vickers, MD, MCOM, BA/BN as co-ordinator.

This medical summary has been written by Professor Vickers and his family team of specialist consultants.

It has been written by medically qualified writers.

Other Diseases We Treat

Empty Nose Syndrome

Pathology: This is described as a rare, late complication of nasal turbinate resection surgery. The commonest clinical symptoms include paradoxical nasal Continue Reading

Read More

Bone and Joint Diseases

Pathology:  Non-union fractures present a problem for the patient and surgeon. With most repair mechanisms in the body a fracture Continue Reading

Read More

Temporo-Mandibular Joint Osteoarthritis

Pathology: The temporo-mandibular joint (TMJ) is the hinge mechanism of the lower jaw. As such it is crucial for the lower Continue Reading

Read More



Get an online consultation with one of our doctors that specialize in stem cell therapy to help you assess if this type of treatment can help with your condition